{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-138214","form_type":"8-K","ticker":null,"cik":"0001604950","company_name":"scPharmaceuticals Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.190182+00:00","generated_at":"2026-06-02T00:50:57.868321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"scPharma Q1 net loss $14.1M; FUROSCIX revenue $6.1M, doses written up 28% QoQ","bullets":["Net FUROSCIX revenue $6.1M vs $2.1M in Q1 2023; gross-to-net discount 19%.","Net loss $14.1M vs $11.2M; cash and equivalents $58.4M at quarter end.","17,376 doses written (+28% QoQ); 8,074 filled (+15% QoQ); 2,938 in-services completed.","Change Healthcare cyberattack estimated 10% negative impact on doses filled in Q1.","FDA PDUFA date August 2024 for Class IV HF indication; PK study for auto-injector underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-138214","json":"https://secwatch.observer/filing/0001193125-24-138214.json","markdown":"https://secwatch.observer/filing/0001193125-24-138214.md","text":"https://secwatch.observer/filing/0001193125-24-138214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604950/000119312524138214/0001193125-24-138214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604950/000119312524138214/d810552d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:50:57.868321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cb30b60200a5e05bb6eda486b04b0bb0aa08dee","claim":"scPharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $6.1 million, net income $14.1 million.","evidence_excerpt":"(EX-99.1) --- EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents of $58.4 million Company to host","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604950/000119312524138214/0001193125-24-138214-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$6.1 million"},{"label":"Net income","value":"$14.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}